Values
Our identity
Consumer protection
Employees & partners
Mission
Environment
Code of conduct
Whistleblowing
Corporate compliance
Policy for the
Prevention of Corruption
Sustainability report
Benefit Company - B Corp
Kip for social
Corporate
Innovative PMI
Nutraceuticals
Profile and organization
Research and development
Company validations
Product certifications
and Declarations
Patents
Trademarks
KIP Academy
Quality & protection
Raw materials choice
Attention to food intolerances
Study about the packs
Information in braille
Tamper Evident system
Conservation and transportation
The nutraceutic module
Products
All products
Neurological Line
Kymax
®
Declinex
®
Uro-Gynecological Line
KIPFeR
®
Almetax
®
Almetax Easy
®
Ivuxur
®
sachets
Ivuxur
®
tablets
Miledix
®
Xinprox
®
Osteoarticular line
Dolatrox
®
Milesax
®
Xinepa
®
Xinepa Easy
®
Doltendix
®
Immunological Line
KIP
®
IMMUNO
Other products
Dolatrox hcc
®
Media
News
Press review
Press kit
Contact Media Relations
Contact
For consumers
For doctors
For pharmacies and health stores
For distributors
For other subjects
Work with us
Where we are
Legal notice
Privacy
E-commerce
Language
Italiano
English
News
News from the world KOLINPHARMA
22/05/2024
-
published at 15.29
KOLINPHARMA®: new patent in China for Doltendix®
KOLINPHARMA® achieved the first patent in China for Doltendix®
29/03/2024
-
published at 15.36
KOLINPHARMA
®
: has received the prize Credit Reputation Award
09/01/2024
-
published at 17.15
Kolinpharma® is pleased to announce the launch of KIPFeR®
KIPFeR® is the nanoparticle iron supplement that Kolinpharma® has launched on the market following a new agreement with Nemysis LTD.
01/09/2023
-
published at 15.09
KOLINPHARMA® has presented Declinex®, initiating the new line of products dedicated for the neurodegenerative diseases
Thanks to the active components such as dry extract of green tea
06/03/2023
-
published at 15.15
Kolinpharma
®
for gender equity a PMIHeroes
Rita Paola Petrelli was being a guest on the podcast PMIHeroes in Ifis Bank
06/12/2022
-
published at 15.23
KOLINPHARMA
®
: has achieved the first patent for Xinprox
®
Now, Kolinpharma has 46 patents in total
23/11/2022
-
published at 15.34
KOLINPHARMA
®
: has achieved the award as “Leader of growth 2023” for the fifth consecutive year
Even this year the company is one between 500 Italian enterprises that they were distinguished for the major growth of turnover
25/10/2022
-
published at 16.47
KOLINPHARMA
®
signs an agreement with ASTAREAL
®
AB for distribution in the Asian market
An important three-year agreement for distribution of products in Mainland China, Hong Kong, Macao and Taiwan
19/11/2021
-
published at 17.03
KOLINPHARMA
®
“Growth Leader 2022” for the fourth consecutive year
The company is confirmed as one of the 450 Italian companies that recorded the highest turnover growth rates
05/08/2021
-
published at 16.06
Kolinpharma
®
at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
KOLINPHARMA
®
strengthens its marketing and brand awareness strategy
26/08/2020
-
published at 14.14
KOLINPHARMA
®
expands its product portfolio with IVUXUR
®
TABLETS.
KOLINPHARMA
®
presents the new product IVUXUR
®
TABLETS, which is added to the other 9 patented or patent pending products
21/05/2020
-
published at 12.38
KOLINPHARMA
®
scales the ranking of nutraceuticals, positioning itself at 76th place. + 4% medical requirements in 1Q 2020 vs 1Q 2019
16/04/2020
-
published at 14.49
KOLINPHARMA
®
:first patent for XINEPA
®
in Israel and fifth outside Italy
Xinepa
®
is a nutraceutical product already in possession of a double patent in Italy
31/03/2020
-
published at 11.48
KOLINPHARMA
®
donates a pulmonary ventilator for the hospitals of city of catanzaro to fight COVID 19
KOLINPHARMA
®
supports physicians and health professionals by becoming a partner in the fundraising initiative "Politeama Foundation
10/03/2020
-
published at 16.45
KOLINPHARMA
®
obtains the patent in the U.S. of Dolatrox
®
It is the fourth patent that is added to Ivuxur
®
and to the 2 of Xinepa
®
30/10/2019
-
published at 12.21
KOLINPHARMA
®
is the first nutraceutical company to obtain UNI ISO 37001 certification
An international standard for management systems to prevent corruption.
17/10/2019
-
published at 12.29
KOLINPHARMA
®
at the Varese Convention on Stock Markets and Corporate Capital
Kolinpharma participated in the Conference "From bond issues to listing: the collection of capital for growth and business development"
24/05/2019
-
published at 10.54
KOLINPHARMA
®
invests in product quality and safety
Strict product controls guarantee quality and safety for the consumer.
01/03/2019
-
published at 17.42
KOLINPHARMA
®
at the Convention about reproduction disorders in Modena
KOLINPHARMA participated as sponsor during the Regional Convention in Emilia Romagna – Right use of food supplement in the most common reproduction disorders
14/02/2019
-
published at 12.45
KOLINPHARMA
®
is getting closer to consumers with new products’ web-sites.
The new web-sites are online, dedicated to KOLINPHARMA’s products
23/01/2019
-
published at 12.12
KOLINPHARMA
®
and the “La Sapienza” University of Rome train future managers.
KOLINPHARMA achieved an agreement with “La Sapienza” University about the organization of a II level Master Degree
21/11/2018
-
published at 17.15
Effective and innovative ASI for osteoarthritis
The SIOT2018 is a reference point for orthopedics
28/06/2018
-
published at 17.07
MILESAX Finalist Project
The excellence in scientific information and the central position of the patient.
28/05/2018
-
published at 09.13
AIM Italia Conference 2018, Milan
May 28th: event with institutional investors
25/05/2018
-
published at 09.19
Growth of medical prescriptions 2018
Reinforcement of sales network. Nominated the International Manager.
13/04/2018
-
published at 09.23
QUOTATION- BONUS: Decree implementing about tax credit
It will be held on April 18th 2018, Milan
10/04/2018
-
published at 09.40
Walk with the SME to the quotation on AIM-Borsa Italiana
The event was organized and invented by IR Top Consulting, partner Equity Markets of Borsa Italiana
05/02/2018
-
published at 09.45
Renovate the certifications by Bureau Veritas
KOLINPHARMA has to renovate its own company and product
05/02/2018
-
published at 09.48
The scientific medical information: an extraordinary job, because it is ethical, scientific and it empathizes with the doctor
KOLINPHARMA always took care about the selection of its collaborators.
05/02/2018
-
published at 09.53
Functional Growth: the policy of “internal growth”
KOLINPHARMA wants to give functional growth opportunities to its own collaborators
05/02/2018
-
published at 09.58
Marketing: a specific science which studies the market
Kolinpharma completed the company organization, including a Junior Product Manager
02/02/2018
-
published at 10.05
The attention to the pharmaceutical forms for an easier patient’s compliance.
The company complements to the traditional pharmaceutical forms, new solutions, easy in their use.
09/01/2018
-
published at 12.16
KOLINPHARMA
®
in the European research
Since 2017, the company faced an international research.
08/01/2018
-
published at 10.13
A QR code which shows itself to who is blind
An international patent highlights the QR-code position to a blind person, thanks to the braille code.
08/01/2018
-
published at 10.16
Tamper evident: ever-changing patented technology
The company adopted a packaging closure, which is usable even for blind people.
02/01/2018
-
published at 12.15
KOLINPHARMA
®
chooses Hoffmann & Eitle Italia as partner
One of the biggest European law firm specialized in patents, models and design and of all internation industrial protection rights.
02/01/2018
-
published at 10.24
A quoted company at AIM, as depositary and logistic: Bomi Group
KOLINPHARMA gave to BOMI Group the storage and the transport of its products to distributors.
02/01/2018
-
published at 10.28
Research and Development team (R&D): effectiveness and innovation
The company’s beating heart, the R&D team, is part of the company.
29/12/2017
-
published at 10.33
The 231, a model which commit us everyday
All the direct and indirect staff, firm the Company Ethical Code, with consciousness and commitment about what it is necessary follow.
21/12/2017
-
published at 10.38
Raw material: a constant research for excellence
The Curcuma is a raw material which everybody talk about, for its scientifically proved qualities.
22/12/2016
-
published at 14.16
2016: KOLINPHARMA
®
revenue redoubles!
The effort of all, from company heart to sales network, has enabled us to reach the target set at the begin of the year: the revenue doubling, touched 2,5 million in 2016.
22/12/2016
-
published at 17.37
All our validations are confirmed.
For 2016, KOLINPHARMA is considered in compliance to ISO 9001 and ISO 22000 requirements. Confirmed also Kosher, Halal, Milk Free, Doping Free, Gluten Free and Casa Savoia requirements. Read all.
22/12/2016
-
published at 16.56
Doping Free Validation: quality and ethic
Even this year, after many controls, it was confirmed the total absence of doping substances and thanks to it, we received the Doping free validation. It guarantees the use of our products by amateur or agonistic athletes.
> Archive News
Media
News
Almetax Easy and tablets
Certified products
Company validations
Consumer Protection
Corporate compliance
Dolatrox
Homepage
Ivuxur
Milesax
Nutraceuticals
Profile and organization
Research and development
Respect the environment
Xinepa Easy and tablets
Press review
Press Kit
Contact media relations
“Science accuracy and listen to people”
“Science accuracy and listen to people”